Balancing Advancement and Affordability Webinar

The CGT Webinar "Balancing Advancement and Affordability: Employer and Consultant Insights on Adopting High-Cost Pharmacy Benefits" explores the adoption of cell and gene therapies (CGTs) and GLP-1 medications in employee benefits programs. It highlights the high costs of CGTs ($250K-$3.5M per treatment) and GLP-1s ($12K-$15K per year) alongside their potential health and financial benefits. The research, based on surveys of 606 business decision-makers and benefits consultants, identifies knowledge gaps, cost concerns, and adoption patterns. Findings reveal that organizations with higher ethical alignment, larger size, stop-loss coverage, and existing GLP-1 benefits are more likely to integrate CGTs. Despite recognition of CGTs' long-term value, upfront costs remain a significant barrier. The study underscores the need for better information-sharing and reframing these therapies as investments rather than expenses.